Drugs Made In America Acquisition Corp. (DMAA) stock
DMAANasdaqBlank ChecksFiscal year ends December 31Also trades as DMAAR, DMAAU
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$10.90+0.00 (0.00%)
Close on Nov 17, 2026Market cap $264.62MP/E –Yield –
Drugs Made In America Acquisition operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Drugs Made In America Acquisition's operating income for the twelve months ending Jun 30, 2026 was -$2.63M. For fiscal 2025 it was -$2.82M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.82M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$136.93K | – |
| Q1 FY2026 | Mar 31, 2026 | -$143.30K | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.09M | – |
| Q3 FY2025 | Sep 30, 2025 | -$263.70K | – |
| Q2 FY2025 | Jun 30, 2025 | -$131.92K | – |
| Q1 FY2025 | Mar 31, 2025 | -$330.93K | – |
| Q3 FY2024 | Sep 30, 2024 | -$144.93K | – |
See a number that looks wrong?